Organon & Co.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OGN research report →
Range $8 – $14
Price Chart
About the company
Organon & Co. , a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive.
- CEO
- Joseph T. Morrissey Jr.
- IPO
- 2021
- Employees
- 10,000
- HQ
- Jersey City, NJ, US
Get TickerSpark's AI analysis on OGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.65B
- P/E
- 17.60
- Fwd P/E
- 4.15
- PEG
- -0.30
- P/S
- 0.60
- P/B
- 3.06
- EV/EBITDA
- 8.31
- Div Yield
- 0.58%
- Gross Margin
- 53.42%
- Op Margin
- 19.49%
- Net Margin
- 3.49%
- ROE
- 22.11%
- ROIC
- 4.65%
Latest fiscal year · YoY change
- Revenue
- $6.22B-2.9%
- Gross Profit
- $3.36B-9.5%
- Op Income
- $1.28B
- Net Income
- $187.00M-78.4%
- EPS
- $0.72-78.6%
- OCF Growth
- -25.5%
- FCF Growth
- -8.5%
- 52W High
- $13.94
- 52W Low
- $5.69
- 50D MA
- $13.77
- 200D MA
- $11.87
- Beta
- 1.52
- RSI (14)
- 64
- Avg Volume
- 2.71M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Organon ended 2025 with $6.2 billion of revenue and guided 2026 to roughly the same level, with cost discipline and debt reduction offsetting product-specific headwinds.· February 12, 2026
- 2025 revenue was $6.2 billion and adjusted EBITDA was $1.9 billion; revenue fell 3% reported and ex FX, while adjusted EBITDA margin stayed essentially flat year over year.
- Nexplanon remained a major pressure point in 2025, down 4% for the year, but the FDA approved an extension from a 3-year to 5-year label, which management says broadens the market long term.
- Biosimilars outperformed expectations, led by Hadlima, which grew 61% ex FX globally for the year; management expects flat to modest biosimilar growth in 2026.
- Organon cut its dividend payout ratio, used excess cash for debt paydown, and received about $390 million of net proceeds from the Jada divestiture to help reduce leverage.
- Management guided 2026 revenue and adjusted EBITDA to about $6.2 billion and about $1.9 billion, with adjusted gross margin expected to decline 75 to 100 basis points and net leverage targeted below 4x by year-end.
Fourth quarter 2025 revenue was $1.57 billion, down 8% at constant currency. Full-year 2025 revenue was $6.2 billion, down 3% reported and ex exchange. Full-year 2025 adjusted EBITDA was $1.9 billion, with adjusted EBITDA margin at 30.7% versus 30.7% in 2024. Fourth-quarter adjusted gross margin was 56.7% versus 60.6% in Q4 2024, and full-year adjusted gross margin was 60.1% versus 61.6% in 2024. Fourth-quarter adjusted net income was $165 million, or $0.63 per diluted share, versus $235 million, or $0.90, a year earlier; full-year adjusted net income was $954 million, or $3.66 per share, versus $1.065 billion, or $4.11. Full-year free cash flow before one-time costs was $960 million, and net leverage ended the year at about 4.3x. For 2026, Organon guided to revenue of about $6.2 billion and adjusted EBITDA of about $1.9 billion, with revenue roughly flat on a constant-currency, pro forma basis after the Jada divestiture, adjusted gross margin down 75 to 100 basis points, interest expense about $500 million, non-GAAP tax rate of 27.5% to 29.5%, and net leverage below 4x by year-end.
Joe Morrissey said 2025 showed Organon can hold profitability while managing major portfolio shifts, including the Atozet LOE, Nexplanon pressure, and policy changes in parts of the business. He emphasized the FDA approval extending Nexplanon to 5 years as a meaningful milestone that could broaden the product’s addressable market, and pointed to Hadlima, Vtama, Emgality, and fertility as offsetting growth drivers. His tone was confident but cautious, stressing balance-sheet repair, disciplined spending, and a focus on maintaining 2026 performance roughly in line with 2025.
Matt Walsh walked through the quarter’s mix of headwinds and offsets, including the $17 million Nexplanon channel impact in Q4, about $20 million of LOE headwind in the quarter, and $30 million of onetime gross-to-net adjustments embedded in price. He said adjusted gross margin fell to 56.7% in Q4 from 60.6% and to 60.1% for the year from 61.6%, with pricing pressure and unfavorable mix as key drivers, while adjusted EBITDA margin held at 30.7% for the full year. On cash and capital allocation, he cited $960 million of free cash flow before one-time costs, about $270 million of restructuring and manufacturing-separation activity in 2025, about $170 million of commercial milestone payments, $66 million of upfront payments, roughly $530 million of debt retired, and expectations for about $100 million of manufacturing-separation costs in 2026.
Analysts focused heavily on whether management has a complete handle on channel and purchasing issues, especially after an earlier Nexplanon investigation and a newly disclosed issue; Carrie Cox declined to add color. Questions also centered on biosimilar policy changes, with management saying FDA draft guidance on comparative efficacy studies looks more incremental than transformational, and on Nexplanon’s 2026 outlook, where management said the product should be roughly flat year over year as ex-U.S. growth and the 5-year label offset U.S. reinsertion loss and channel pressure. Other notable topics included the pace of OpEx savings, the new Nexplanon REMS program, which management said should be manageable because existing prescribers can be recertified in about 15 to 20 minutes, and the CEO search, for which the board said no public update was available.
The bull case from the call is that Organon appears able to keep revenue and EBITDA roughly stable in 2026 despite a difficult mix of LOEs, pricing pressure, and product-specific headwinds. Management highlighted durable growth engines in Hadlima, Vtama, Emgality, fertility outside China, and Nexplanon ex-U.S., along with a new 5-year Nexplanon label that could expand the long-term market. The company also showed concrete balance-sheet progress through debt paydown, Jada proceeds, and a target to get net leverage below 4x.
The bear case is that several core businesses remain under pressure: Nexplanon faces policy, channel, and reinsertion headwinds; fertility is expected to be a headwind in 2026; and established brands still carry respiratory and LOE-related declines. Gross margin is expected to fall another 75 to 100 basis points in 2026, and management acknowledged that Q1 could look like a weak quarter and that reinsertion-related Nexplanon pressure could still linger into 2027. Analyst concerns about whether the company has fully uncovered all channel issues also added to skepticism around internal controls and execution.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.4%
- Shares Outstanding
- 262.62M
- Float Shares
- 260.94M
of shares held by institutions
664 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for OGN, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Kevin HernHouse · OK01 | Sell | Aug 5, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Aug 5, 26 | Filing → |
| Gary C. PetersSenate · MI | Sell | Jul 10, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Nov 3, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Oct 2, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jul 28, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jun 29, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | May 19, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Apr 25, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Mar 14, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Sep 14, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Sep 14, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Sep 22, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Sep 15, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 36.92M | ▲ 987.98K |
| Blackrock, Inc. | 31.92M | ▼ 134.97K |
| Pentwater Capital Management LP | 18.10M | ▲ 18.10M |
| Vanguard Portfolio Management LLC | 15.35M | ▲ 221.19K |
| Vanguard Capital Management LLC | 11.92M | ▲ 6.75K |
| Fil Ltd | 10.50M | ▲ 10.50M |
| State Street Corp | 9.76M | ▲ 99.93K |
| Goldman Sachs Group Inc | 5.20M | ▲ 3.59M |
| Alliancebernstein L.P. | 4.75M | ▲ 4.03M |
| Geode Capital Management, LLC | 4.64M | ▼ 173.30K |
| Ubs Group AG | 4.45M | ▼ 405.62K |
| Man Group PLC | 4.18M | ▲ 4.18M |
Held by 441 ETFs
Biggest fund positions in OGN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | Drinane Juliana Papa | other | 21,872 |
| Nov 13, 26 | Drinane Juliana Papa | other | 21,872 |
| Nov 13, 26 | Drinane Juliana Papa | other | 7,492 |
| Nov 13, 26 | Morrissey Joseph T. Jr. | other | 43,744 |
| Nov 13, 26 | Morrissey Joseph T. Jr. | other | 13,551 |
| Nov 13, 26 | Morrissey Joseph T. Jr. | other | 43,744 |
| Nov 7, 26 | Drinane Juliana Papa | other | 3,626 |
| Nov 7, 26 | Drinane Juliana Papa | other | 1,242 |
| Nov 7, 26 | Drinane Juliana Papa | other | 3,626 |
| Nov 7, 26 | Arjona Ferreira Juan Camilo | other | 6,447 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OGN coverage
Recent articles, reports, and earnings notes.
No research on OGN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OGN report →Organon Presents New Analysis of Pooled Post-Hoc Phase 3 Data on VTAMA® (tapinarof) cream, 1%, Demonstrating Consistent Efficacy in Atopic Dermatitis Across Diverse Patient Subgroups at ACAAI
businesswire.com · Nov 12
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
zacks.com · Nov 10
Contrasting CASI Pharmaceuticals (NASDAQ:CASI) and Organon & Co. (NYSE:OGN)
defenseworld.net · Nov 3
Organon (OGN) Q3 Earnings and Revenues Top Estimates
zacks.com · Oct 30
Organon Announces Quarterly Dividend
businesswire.com · Oct 30
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
zacks.com · Oct 26
Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
businesswire.com · Oct 19
Organon & Co. (NYSE:OGN) & Xeris Biopharma (NASDAQ:XERS) Critical Comparison
defenseworld.net · Oct 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.